LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidru

SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platfor...

Related Keywords

United States ,New York ,London ,City Of ,United Kingdom ,Zina Affas Besse ,Camilla Petrycer Hansen ,Kabeer Aziz ,Limmatech Bio ,Alexander Siebert ,Hooft Van Huijsduijnen ,Franz Werner Haas ,Limmatech Biologics ,Trophic Communications ,Novo Holdings ,Novo Holding ,National Overview ,United States Centers For Disease ,World Health Organization ,Impact Fund ,Principal At Novo Holdings ,Novo Nordisk Foundation ,Infective Resistance Impact Fund ,Adjuvant Capital ,Affas Besse ,Deputy Head ,Private Equity ,Petrycer Hansen ,Antimicrobial Resistance ,United States Centers ,Disease Control ,Anti Infective Resistance ,Novo Nordisk ,Resistance Collaborators ,Retrieved August ,Exploring Shigella ,Werner Haas ,